Free for academic non-profit institutions. Other users need a Commercial license
FPR2 (Formyl Peptide Receptor 2) is a Protein Coding gene. Diseases associated with FPR2 include Rubeosis Iridis and Alzheimer Disease. Among its related pathways are Signaling by GPCR and Peptide ligand-binding receptors. Gene Ontology (GO) annotations related to this gene include G protein-coupled receptor activity and N-formyl peptide receptor activity. An important paralog of this gene is FPR3.
The formyl peptide receptor family, FPR1, FPR2 and FPR3 (formerly FPR, FPRL1 and FPRL2 respectively) are Gi-protein-coupled receptors that are expressed mainly by mammalian phagocytic leukocytes. FPRs are involved in antibacterial host defence and inflammation.
GeneHancer (GH) Identifier | GH Type | GH Score |
GH Sources | Gene Association Score | Total Score | TSS distance (kb) | Number of Genes Away | Size (kb) | Transcription Factor Binding Sites |
Gene Targets |
---|---|---|---|---|---|---|---|---|---|---|
GH19J051749 | Promoter/Enhancer | 1.4 | EPDnew FANTOM5 Ensembl ENCODE | 280.6 | -1.4 | -1425 | 4 | JUND SPI1 CEBPB ATF3 | FPR1 FPR2 piR-38580-149 SIGLEC10 ZNF350 HSALNG0127255 HAS1 | |
GH19J051760 | Promoter | 0.4 | EPDnew | 250.4 | +8.9 | 8901 | 0.1 | POLR2A | FPR2 piR-41525-349 HSALNG0127256 FPR3 FPR1 | |
GH19J051761 | Promoter | 0.4 | EPDnew | 250.4 | +9.1 | 9135 | 0.1 | POLR2A | FPR2 piR-41525-349 HSALNG0127256 FPR3 FPR1 | |
GH19J051731 | Enhancer | 1.2 | FANTOM5 Ensembl ENCODE | 37.8 | -13.4 | -13425 | 16.8 | ZNF395 GABPA VEZF1 TAL1 FOSL1 SPI1 ATF1 POLR2A MAX TCF12 | HSALNG0127254 FPR1 FPR2 HAS1 FPR3 SIGLEC10 SIGLEC14 MIR125A MIR99B MIRLET7E | |
GH19J051621 | Enhancer | 1.3 | FANTOM5 Ensembl ENCODE dbSUPER | 34.7 | -131.2 | -131225 | 2.8 | BCL11A IRF4 CBFB SPI1 BHLHE40 BATF POLR2A MYC IRF5 MAX | RPL9P33 lnc-ZNF175-4 FPR2 FPR1 SIGLEC14 SIGLEC10 ZNF350 SIGLEC5 HSALNG0127238 ENSG00000268500 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0001540 | amyloid-beta binding | ISS | -- |
GO:0004875 | complement receptor activity | IBA | 21873635 |
GO:0004930 | G protein-coupled receptor activity | IEA,NAS | 11316806 |
GO:0004982 | N-formyl peptide receptor activity | IEA,IBA | 21873635 |
GO:0005124 | scavenger receptor binding | IPI | 20141570 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005737 | cytoplasm | ISS | -- |
GO:0005886 | plasma membrane | IEA,TAS | -- |
GO:0016020 | membrane | IEA | -- |
GO:0016021 | integral component of membrane | IEA | -- |
GO:0035579 | specific granule membrane | TAS | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Peptide ligand-binding receptors |
.34
|
|
2 | Akt Signaling |
Akt Signaling
.60
p38 Signaling
.60
|
Tec Kinases Signaling
.55
|
3 | Signaling by GPCR | ||
4 | Innate Immune System |
.61
|
|
5 | RET signaling |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0001774 | microglial cell activation | ISS | -- |
GO:0001934 | positive regulation of protein phosphorylation | IGI | 20141570 |
GO:0002430 | complement receptor mediated signaling pathway | IBA | 21873635 |
GO:0002768 | immune response-regulating cell surface receptor signaling pathway | IDA | 25505240 |
GO:0006898 | receptor-mediated endocytosis | ISS | -- |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
LL-37 | Investigational | Pharma | Agonist, Full agonist | 0 | ||
WKYMVM | Pharma | Agonist, Full agonist | Selective FPR2 and FPR3 receptor agonist | 0 | ||
FPR A14 | Pharma | FPR agonist | 0 | |||
MMK 1 | Pharma | Potent and selective FPR2 agonist | 0 | |||
N-Formyl-Met-Leu-Phe | Pharma | Endogenous FPR1 agonist | 0 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
amyloid β<sub>42</sub> |
|
Agonist, Full agonist |
|
Compound | Action | Cas Number |
---|---|---|
FPR A14 | FPR agonist | 329691-12-5 |
MMK 1 | Potent and selective FPR2 agonist | 271246-66-3 |
N-Formyl-Met-Leu-Phe | Endogenous FPR1 agonist | 59880-97-6 |
WKYMVM | Selective FPR2 and FPR3 receptor agonist | 187986-11-4 |
Compound | Action | Cas Number |
---|---|---|
Ac9-25 | 284040-76-2 | |
Boc-MLF | 67247-12-5 | |
Cyclosporin H | Selective and competitive formyl peptide receptor antagonist | 83602-39-5 |
FPR A14 | 329691-12-5 | |
MMK 1 | 271246-66-3 | |
N-Formyl-Met-Leu-Phe | 59880-97-6 | |
PBP 10 | 794466-43-6 | |
WKYMVM | 187986-11-4 | |
WRW4 | 878557-55-2 |
ExUns: | 1a | · | 1b | ^ | 2a | · | 2b | ^ | 3a | · | 3b | · | 3c |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | ||||||||||||
SP2: | - | - | |||||||||||
SP3: |
This gene was present in the common ancestor of chordates.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Chimpanzee (Pan troglodytes) |
Mammalia | FPR2 30 31 |
|
OneToOne | |
Dog (Canis familiaris) |
Mammalia | FPR2 30 |
|
||
Mouse (Mus musculus) |
Mammalia | Fpr2 30 17 31 |
|
OneToMany | |
Fpr3 31 |
|
OneToMany | |||
Rat (Rattus norvegicus) |
Mammalia | Fpr2 30 |
|
||
Oppossum (Monodelphis domestica) |
Mammalia | -- 31 |
|
ManyToMany | |
-- 31 |
|
ManyToMany | |||
Lizard (Anolis carolinensis) |
Reptilia | -- 31 |
|
OneToMany | |
Zebrafish (Danio rerio) |
Actinopterygii | zgc:194202 31 |
|
ManyToMany |
SNP ID | Clinical significance and condition | Chr 19 pos | Variation | AA Info | Type |
---|---|---|---|---|---|
rs74602258 | Benign: not provided | 51,768,878(+) |
T/C NM_001005738.2(FPR2):c.220T>C (p.Phe74Leu) |
MISSENSE |
Variant ID | Type | Subtype | PubMed ID |
---|---|---|---|
dgv1067e212 | CNV | gain | 25503493 |
dgv143e55 | CNV | gain | 17911159 |
dgv3625n100 | CNV | gain | 25217958 |
dgv3626n100 | CNV | gain | 25217958 |
dgv6523n54 | CNV | gain | 21841781 |
esv2758767 | CNV | gain+loss | 17122850 |
nsv1140251 | OTHER | inversion | 24896259 |
nsv458733 | CNV | gain | 19166990 |
nsv470151 | CNV | gain | 18288195 |
nsv524403 | CNV | gain | 19592680 |
nsv579997 | CNV | gain | 21841781 |
Disorder | Aliases | PubMed IDs |
---|---|---|
rubeosis iridis |
|
|
alzheimer disease |
|
|
bacterial infectious disease |
|
|